Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)’s share price rose 2.5% on Friday . The stock traded as high as $8.64 and last traded at $8.64, with a volume of 64,702 shares trading hands. The stock had previously closed at $8.43.

FOMX has been the subject of several recent research reports. Guggenheim restated a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a report on Tuesday, August 16th. Finally, TheStreet upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd.

The firm’s 50-day moving average is $7.83 and its 200-day moving average is $6.77. The firm’s market capitalization is $264.91 million.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.02. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.10 million. Analysts anticipate that Foamix Pharmaceuticals Ltd. will post ($0.92) earnings per share for the current fiscal year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.